Commerzbank Ag set a €109.00 ($128.24) price objective on Merck KGaA (FRA:MRK) in a research report report published on Wednesday. The firm currently has a neutral rating on the healthcare company’s stock.
Other analysts have also issued research reports about the stock. Nord/LB reiterated a neutral rating on shares of Merck KGaA in a research note on Wednesday, June 28th. equinet AG set a €91.00 ($107.06) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, April 25th. Credit Suisse Group set a €106.00 ($124.71) target price on shares of Merck KGaA and gave the stock a neutral rating in a research note on Wednesday, July 26th. DZ Bank AG reiterated a neutral rating on shares of Merck KGaA in a research note on Monday, May 29th. Finally, Kepler Capital Markets set a €119.00 ($140.00) target price on shares of Merck KGaA and gave the stock a buy rating in a research note on Monday, July 31st. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and six have assigned a buy rating to the stock. Merck KGaA presently has an average rating of Hold and an average price target of €108.76 ($127.96).
Merck KGaA (FRA:MRK) opened at 92.091 on Wednesday. The company’s 50-day moving average is €99.73 and its 200 day moving average is €103.87. Merck KGaA has a one year low of €89.00 and a one year high of €115.00. The firm has a market cap of €40.04 billion and a PE ratio of 24.007.
TRADEMARK VIOLATION NOTICE: This report was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/08/12/commerzbank-ag-reiterates-109-00-price-target-for-merck-kgaa-mrk.html.
Merck KGaA Company Profile
What are top analysts saying about Merck KGaA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merck KGaA and related companies.